<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> has been associated with an increased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e>, both <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> defining and non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AIDS</z:e> defining </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: This study presents a detailed pathological description of newly diagnosed <z:hpo ids='HP_0002665'>lymphomas</z:hpo> in Johannesburg, South Africa (January 2004 and December 2006) </plain></SENT>
<SENT sid="2" pm="."><plain>The review coincides with introduction of combination antiretroviral therapy </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: One thousand eight hundred and ninety-seven new <z:hpo ids='HP_0005523'>lymphoproliferative disorders</z:hpo> were referred to the Charlotte Maxeke Johannesburg Academic Hospital </plain></SENT>
<SENT sid="4" pm="."><plain>B-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> accounted for 83%, T-cell non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 3.5%, and Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> 7% of cases </plain></SENT>
<SENT sid="5" pm="."><plain>The overall prevalence of <z:e sem="disease" ids="C0019693" disease_type="Disease or Syndrome" abbrv="">HIV infection</z:e> was 37% (n = 709) </plain></SENT>
<SENT sid="6" pm="."><plain>Diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (21%; n = 401) was the most common <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>HIV prevalence ranged from an absence in follicular or mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> to a low prevalence in diseases like small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (4%) and pre-B/<z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">common ALL</z:e> (5%) to a high prevalence in diffuse large B-cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (80%), Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo>/<z:hpo ids='HP_0001909'>leukemia</z:hpo> (86%), and primary effusion <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (100%) </plain></SENT>
<SENT sid="8" pm="."><plain>CONCLUSIONS: This study provides a baseline for monitoring the impact of HIV and management thereof on <z:hpo ids='HP_0002665'>lymphoma</z:hpo> trends </plain></SENT>
<SENT sid="9" pm="."><plain>The high prevalence of HIV in certain <z:hpo ids='HP_0002665'>lymphoma</z:hpo> categories emphasizes the need for capacity to diagnose and manage dual conditions </plain></SENT>
<SENT sid="10" pm="."><plain>This study highlights the need for strengthening of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> registries within South Africa and the region </plain></SENT>
</text></document>